Nasofan (Fluticasone Propionate)

Fluticasone Propionate, the active ingredient in Nasofan, is a corticosteroid presented as a nasal spray for endosinusial use. It is indicated for inflammatory conditions of the nasal passages such as allergic rhinitis, nasal polyps and chronic sinusitis, helping to reduce swelling and symptom severity. GNH USA supplies Nasofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluticasone Propionate acts locally in the nasal mucosa to control inflammation associated with several upper‑respiratory conditions.

Allergic rhinitis: reduces nasal congestion, itching and sneezing caused by allergen exposure. Nasal polyps: decreases polyp size and improves nasal airflow. Chronic sinusitis: alleviates mucosal swelling and promotes sinus drainage.

Fluticasone Propionate is generally well tolerated when used as directed, but local and systemic adverse reactions can occur.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleeds) - Headache - Sore throat or cough - Altered taste or oral dryness - Sneezing shortly after administration

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use - Development of cataracts or glaucoma - Fungal infection of the nasal passages - Severe or persistent nosebleeds - Hypersensitivity reactions such as angioedema

Before using Nasofan, consider the following safety measures.

Prescribe only as needed: avoid unnecessary long‑term use. Monitor for infection: discontinue if signs of fungal or bacterial infection appear. Assess ocular health: patients with glaucoma or cataracts should use with caution. Check systemic exposure: patients on systemic steroids may have increased risk of systemic effects. Evaluate metabolic conditions: diabetics should monitor blood glucose as corticosteroids can affect glucose control. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluticasone Propionate may interact with other medications that influence corticosteroid metabolism or systemic exposure.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that can increase systemic levels. - Concurrent systemic corticosteroids, raising risk of systemic side effects. - Ritonavir or other potent protease inhibitors that markedly inhibit metabolism.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) may modestly raise exposure. - Antifungal agents such as fluconazole. - Certain antiretroviral drugs (e.g., efavirenz) that may alter steroid clearance.